Follow-up of Patients With Uveal Melanoma Adapted to the Risk of Relapse (SALOME)
About this study
Biomarkers search for early diagnosis of liver metastases in patients with uveal melanoma who benefit from a follow-up tailored to their personalized risk of relapse.
- Condition
- Uveal Melanoma
- Tested
- Blood test
- Sponsor
- Institut Curie
Who can join
- Age
- 18 years and older
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 9
- Minimum age: 18 years
- Study condition: Uveal Melanoma
- Patient aged of 18 years or more.
- Patient with uveal melanoma with high metastatic relapse risk defined as :
- T2b/c/d ou ≥ T3,
- or chromosom 3 or chromosom 8 abnormality by CGH array.
- Completion of treatment of the primary tumor ≤ 2 months.
- Patient able to comply with the schedule of visits and blood samples of the study.
- Signed informed consent form or legal representative.
Exclusion 2
- Patient without french social insurance.
- Any social, medical or psychological condition making the research process impossible.
Where
1 site, 1 recruiting
Institut Curie
Paris, France
Contact
-
Sophie Piperno-Neumann, MD
01 44 32 46 72 sophie.piperno-neumann@curie.fr
-
Marie-Emmanuelle Legrier, PhD
01 56 24 56 49 drci.promotion@curie.fr
Potential match only. Final eligibility is determined by the study team.